FindTrial
Sign In

Middle meningeal artery embolization for the treatment of chronic subdural hemorrhage (Message)

Middle meningeal artery embolization for the treatment of chronic subdural hemorrhage (Message)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047232
Enrollment
Unknown
Registered
2021-06-11
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial aneurysm

Interventions

Experimental group1:Embolization
Experimental group2:Conventional treatment
Experimental group3:Borehole drainage

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. CSDH patients with convex brain involvement, thickness less than 10 mm, or space-occupying effects (flattened cortex or midline shift); 2. In good physical condition.

Exclusion criteria

Exclusion criteria: 1. CSDH that had a focal location (confined to the frontal or temporal base or the interhemispheric space without cerebral convexity involvement); 2. CSDH that developed with underlying conditions (vascular lesions, brain tumor, arachnoid cyst, spontaneous intracranial hypotension, or previous craniotomy); 3. Life expectancy of less than 6 months.

Design outcomes

Primary

MeasureTime frame
Hemorrhage recurrence or progression;Complications;—

Countries

China

Contacts

Public ContactLiu Aihua

Beijing Tiantan Hospital, Capital Medical University

18401657289@163.com+86 15901398688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026